Company patents

Roche Diagnostics Operations, Inc.

Roche Diagnostics Operations, Inc. surprisingly shows a strong emerging focus in Computer Security, with patent filings increasing by 150.0% year-over-year in 2026 (so far), despite its core Material & Chemical Analysis category, representing 69.1% of its portfolio, experiencing a significant decline of 18.0% in 2025 and 64.6% so far in 2026.

Patent Trend by Technology Area

Yearly patent publications since 2023

Product themes

Product-level themes inferred from filings since 2023, with category chips showing where each theme appears. Select a theme to filter the patents below.

447 US filings (since 2023) · 12 categories · 21 themes

Advanced Biomarker Detection Assays

Methods and compositions for identifying, quantifying, or characterizing specific biological molecules (e.g., nucleic acids, proteins, metabolites, antibodies) or microbial species, often for diagnostic, prognostic, or quality control applications.

Material & Chemical Analysis
Who else files here? →
236since 2023
-30.9%YoY
Integrated Molecular Diagnostic Systems

Self-contained or modular devices designed to automate and integrate multiple steps of molecular diagnostic assays, from sample preparation to result interpretation, often for point-of-care or high-throughput applications.

Laboratory ApparatusGenetic & Microbiological Assays
Who else files here? →
143since 2023
-29.4%YoY
Automated Liquid Handling

Systems and components designed for precise, automated manipulation, transfer, and dispensing of liquid samples and reagents, often involving pipettes, robotic arms, and specialized sample containers.

Laboratory Apparatus
Who else files here? →
114since 2023
+2.9%YoY
Physiological Monitoring & Diagnostics

Systems and methods for non-invasive or minimally invasive collection and analysis of physiological data (e.g., blood pressure, electrolytes, genetic markers, B cell repertoire) to assess patient health status, screen for conditions, or aid in diagnosis.

Healthcare Informatics
Who else files here? →
36since 2023
-41.7%YoY
Antibody Engineering & Therapeutics

Design and modification of antibodies or antibody-derived fragments for targeted therapeutic intervention, including bispecific formats, Fc region modifications, and activatable constructs.

Material & Chemical AnalysisPeptides & Proteins
Who else files here? →
24since 2023
-11.1%YoY
Smart Medication Management

Systems that integrate digital technology, sensors, or connectivity to monitor, track, or automate aspects of medication administration, often providing data feedback, personalized recommendations, or secure logging.

Healthcare Informatics
Who else files here? →
21since 2023
-70.0%YoY
Molecular Biomarkers for Disease

Identification and measurement of specific nucleic acid sequences (DNA, RNA), their expression levels, or epigenetic modifications (e.g., methylation) as indicators for disease presence, progression, risk, or treatment response.

Genetic & Microbiological Assays
Who else files here? →
20since 2023
+100.0%YoY
Ion Implantation Control & Metrology

Methods and apparatus for precise wafer positioning, ion beam uniformity, and dose monitoring during ion implantation processes in semiconductor device manufacturing.

Electron / Ion Tubes & Discharge
Who else files here? →
10since 2023
+200.0%YoY
AI for Medical Diagnostics

Utilizing machine learning, particularly deep learning, to analyze medical data such as images, sensor readings, or physiological signals for disease prediction, diagnosis, or treatment assessment.

Healthcare InformaticsImage ProcessingComputer Vision
Who else files here? →
10since 2023
+33.3%YoY
Bioprocess Development for Proteins

Methods and systems for the efficient and scalable production, purification, and formulation of proteins and peptides, including fermentation, chromatography, and cell-based expression systems.

Peptides & Proteins
Who else files here? →
10since 2023
+50.0%YoY
Thermal Control for Bio-Reactions

Apparatus and methods for precisely controlling temperature profiles (heating, cooling, incubation) within laboratory reaction vessels or modules to optimize biochemical processes like gene amplification or protein assays.

Laboratory Apparatus
Who else files here? →
9since 2023
+200.0%YoY
Secure Data Sharing & Rights Management

Mechanisms to facilitate the secure exchange of data between different entities or systems while enforcing usage policies, managing digital content rights, and ensuring data consistency during replication or transfer.

Computer Security
Who else files here? →
6since 2023
+100.0%YoY
Automated Visual Inspection

Systems that employ imaging and image processing to automatically detect defects, verify states, or ensure quality control in manufactured goods, printed materials, or industrial processes.

Material & Chemical Analysis
Who else files here? →
6since 2023
+100.0%YoY
Rapid Isothermal Amplification

Methods and kits for amplifying nucleic acids at a constant temperature, enabling faster results and point-of-care applications, often used for pathogen or contamination detection.

Genetic & Microbiological Assays
Who else files here? →
6since 2023
n/a
Microfluidic Lab-on-Chip Devices

Miniaturized devices that manipulate small volumes of fluids (nanoliters to picoliters) through microchannels to perform laboratory functions like mixing, separation, reaction, and detection on a single chip.

Laboratory Apparatus
Who else files here? →
5since 2023
+100.0%YoY
Secure Data Storage & Provenance

Techniques for protecting data at rest or in backup, ensuring its integrity, confidentiality, and verifiable origin, often involving encryption, unique identifiers, or secure repositories.

Computer SecurityNetwork Security & Access Control
Who else files here? →
4since 2023
+100.0%YoY
Protein & Peptide Engineering

Modification of protein or peptide sequences, structures, or post-translational modifications (e.g., glycosylation, lipidation) to enhance their stability, solubility, delivery, or therapeutic efficacy.

Peptides & Proteins
Who else files here? →
4since 2023
0.0%YoY
Immunomodulatory Protein Design

Design and engineering of proteins or peptides to directly modulate immune responses, including enhancing antigen presentation, suppressing inflammation, or activating specific immune cell types.

Peptides & Proteins
Who else files here? →
3since 2023
new
Targeted Small Molecule Therapeutics

Design and synthesis of acyclic or carbocyclic organic compounds that selectively modulate specific biological targets or pathways for the treatment of diseases.

Heterocyclic Compounds (Pharma)
Who else files here? →
3since 2023
+100.0%YoY
Wearable Physiological Sensing

Development of devices and methods for non-invasive or minimally invasive collection and analysis of physiological data, often from wearable sensors, to monitor health, activity, or specific conditions.

Medical Diagnostics & Surgery
Who else files here? →
1since 2023
new
Chemical Synthesis of Drug Intermediates

Processes and methodologies for the efficient and scalable preparation of complex heterocyclic compounds and their precursors, including specific reaction conditions, purification techniques, and intermediate compounds.

Heterocyclic Compounds (Pharma)
Who else files here? →
1since 2023
n/a

Patents

Showing 81-90 of 745

Page 9 of 75
US 20250290940 A1APPLICATION
G01N35/00

METHOD FOR DETERMINING A DILUTION FACTOR OF A SAMPLE

Filed:2023-04-28Pub:2025-09-18
Applicant:Roche Diagnostics Operations, Inc.

A method for determining a dilution factor of a sample comprising an analyte ( 115 ) of interest is disclosed. The method comprises the following steps: a) ( 136 ) preparing a mixture ( 113 ) by diluting defined volumes of calibrators ( 114 ) comprising the analyte ( 115 ) of interest with a defined volume of a dilution reagent comprising at least one first internal standard ISTDa ( 118 ); b) ( 138 ) performing at least one sample preparation workflow ( 120 ) on a defined volume of the mixture ( 113 ) thereby generating a prepared mixture ( 122 ), wherein the sample preparation workflow ( 120 ) comprises adding at least one second internal standard ISTDb ( 124 ); c) ( 140 ) performing at least one sample measurement on the prepared mixture ( 122 ) comprising determining a peak area for each of the first internal standard ISTDa ( 118 ) and the second internal standard ISTDb ( 124 ) using an in vitro diagnostic medical device ( 110 ) and determining an area ratio AR sample of ISTDa ( 118 ) and ISTDb ( 124 ) by using at least one processing device ( 130 ); d) ( 142 ) performing at least one calibration measurement on a plurality of calibration samples ( 128 ), wherein the calibration samples ( 128 ) have a predefined concentration of ISTDa ( 118 ) and ISTDb ( 124 ), and determining an averaged area ratio AR calibration,av of ISTDa ( 118 ) and ISTDb ( 124 ) of the calibration samples ( 128 ) by using the processing device ( 130 ); e) ( 144 ) determining the dilution factor by determining a deviation of the area ratio AR sample and the averaged area ratio AR calibration,av by using the processing device ( 130 ).

US 12411129 B2GRANTED
G01N33/53

Reduction of interferences in immunoassays

Filed:2020-09-08Pub:2025-09-09
Applicant:Roche Diagnostics Operations, Inc.

The present invention relates to a method for determining an analyte in a sample, comprising a) contacting said sample with at least a first and a second detector compound; b) determining the amount of complexes comprising at least one detector compound; and, c) determining said analyte in a sample based on the result of step b), wherein said first detector compound comprises a first binding moiety and a first label, and said second detector compound comprises a second binding moiety and a second label, and wherein the first label and the second label are non-identical. The present invention further relates to a kit for detecting an analyte in a sample, comprising at least a first and a second detector compound for said analyte, wherein said first detector compound comprises a first binding moiety and a first label, and said second detector compound comprises a second binding moiety and a second label, and wherein the first label and the second label are non-identical; and to a device for determining an analyte in a sample, comprising at least a first and a second detector compound for said analyte, wherein said first detector compound comprises a first binding moiety and a first label, and said second detector compound comprises a second binding moiety and a second label, and wherein the first label and the second label are non-identical; and means for determining at least one signal obtained from said first label and said second label; and to the use of a composition comprising at least a first and a second detector compound for detecting an analyte, wherein said first detector compound comprises a first binding moiety and a first label, and said second detector compound comprises a second binding moiety and a second label, and wherein the first label and the second label are non-identical.

US 20250277801 A1APPLICATION
G01N33/74

DERIVATISATION AGENT FOR LASER DESORPTION IONIZATION MASS SPECTROMETRY

Filed:2025-05-16Pub:2025-09-04
Applicant:Roche Diagnostics Operations, Inc.

In a first aspect, the invention relates to a derivatisation agent, preferably derivatisation agent for analytes intended to be analysed via LDI-MS, comprising a structural element of formula (I) C-L1-Z-(L2) p -X, wherein C is a chromophore having an absorption maximum in the range of from 280 to 400 nm; Z is a charged unit comprising at least one permanently charged moiety; X is a reactive group; L1, L2 are each a linker unit; and p is either zero or 1. A second aspect of the invention is related to a kit comprising the derivatisation agent according to the first aspect. In a third aspect, the invention is directed to a use of the derivatisation agent according to the first aspect for the mass spectrometric determination of an analyte molecule, wherein the mass spectrometric determination is LDI-MS. A fourth aspect of the invention relates to a conjugate of a derivatisation agent according to the first aspect and an analyte, wherein the conjugate has the structure of formula (II) C-L1-Z-(L2) p -Xa-Ya-A, wherein C, L1, L2, p, Z and N are as defined in the context of the first aspect; Xa is a remainder of a reactive group X as defined in the context of the first aspect; A is the analyte and Ya is the remainder of a reactive group Y bound to the analyte A, which has reacted with the reactive group X of the derivatisation agent thus forming a covalent bound between Xa and Ya. A fifth aspect of the invention is related to a method for the mass spectrometric determination of an analyte molecule comprising the steps: (a) providing an analyte of interest; (b) providing a derivatisation agent comprising a structure of formula (I) as defined in the context of the first aspect; (c) reacting the analyte provided according to (a) with the derivatisation agent provided according to (b), whereby a conjugate of the analyte and the derivatisation agent is formed, and (d) subjecting the conjugate formed in (c) to a mass spectrometric analysis, wherein the mass spectrometric analysis is preferably LDI-MS.

1891075